ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
value factor · long-only model fund

Foundry Healthcare CashProd Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FCAHHYPOTHETICAL MODEL
Since ’99
+192%
Expense Ratio
0.45%
placeholder
Holdings
100
cap-weighted
Inception
Apr 2019
placeholder
Full Sharpe
0.31
Ann. Return (LS)
5.4%
Ann. Volatility
17.4%
Max Drawdown
-51.5%
Test Sharpe ’19–26
0.04
Test FF5 α (ann.)
0.5%
vs Fama-French 5
Test FF5 α t-stat
0.10
not significant
Monthly turnover
13%
of the long leg, per rebalance
Cumulative return (LS)
192%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.68
what this fund holds
Long leg ann. return
12.6%
buyable, long-only
Long-short Sharpe
0.31
requires shorting
Bottom bucket ann. return
7.2%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

100 of 100 · 100.0% of book
TickerCompanySectorMarket capWeight
1PFE
PFIZER INCHealthcare$142.77B
14.50%
2CVS
CVS HEALTH CORPHealthcare$137.12B
13.92%
3ELV
ELEVANCE HEALTH INCHealthcare$80.92B
8.22%
4CI
CIGNA GROUPHealthcare$74.45B
7.56%
5COR
CENCORA INCHealthcare$59.91B
6.08%
6CAH
CARDINAL HEALTH INCHealthcare$53.52B
5.43%
7HUM
HUMANA INCHealthcare$48.02B
4.88%
8BDX
BECTON DICKINSON & COHealthcare$43.58B
4.43%
9TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTDHealthcare$37.30B
3.79%
10CNC
CENTENE CORPHealthcare$32.81B
3.33%
11GEHC
GE HEALTHCARE TECHNOLOGIES INCHealthcare$28.69B
2.91%
12VTRS
VIATRIS INCHealthcare$20.14B
2.04%
13ZBH
ZIMMER BIOMET HOLDINGS INCHealthcare$17.63B
1.79%
14THC
TENET HEALTHCARE CORPHealthcare$16.79B
1.70%
15DVA
DAVITA INCHealthcare$15.21B
1.54%
16SOLV
SOLVENTUM CORPHealthcare$14.08B
1.43%
17ELAN
ELANCO ANIMAL HEALTH INCHealthcare$12.90B
1.31%
18MOH
MOLINA HEALTHCARE INCHealthcare$11.74B
1.19%
19BAX
BAXTER INTERNATIONAL INCHealthcare$11.68B
1.19%
20HSIC
HENRY SCHEIN INCHealthcare$10.00B
1.02%
21UHS
UNIVERSAL HEALTH SERVICES INCHealthcare$9.15B
0.93%
22OSCR
OSCAR HEALTH INCHealthcare$8.77B
0.89%
23BIO
BIO-RAD LABORATORIES INCHealthcare$8.15B
0.83%
24TFX
TELEFLEX INCHealthcare$5.96B
0.61%
25BLCO
BAUSCH & LOMB CORPHealthcare$5.80B
0.59%
26NVST
ENVISTA HOLDINGS CORPHealthcare$4.35B
0.44%
27WAY
WAYSTAR HOLDING CORPHealthcare$4.27B
0.43%
28ICUI
ICU MEDICAL INCHealthcare$3.94B
0.40%
29BKD
BROOKDALE SENIOR LIVING INCHealthcare$3.58B
0.36%
30OGN
ORGANON & COHealthcare$3.55B
0.36%
31ITGR
INTEGER HOLDINGS CORPHealthcare$3.24B
0.33%
32ACHC
ACADIA HEALTHCARE COMPANY INCHealthcare$3.17B
0.32%
33XRAY
DENTSPLY SIRONA INCHealthcare$2.81B
0.29%
34PBH
PRESTIGE CONSUMER HEALTHCARE INCHealthcare$2.36B
0.24%
35NEOG
NEOGEN CORPHealthcare$2.24B
0.23%
36SGRY
SURGERY PARTNERS INCHealthcare$2.09B
0.21%
37SNDA
SONIDA SENIOR LIVING INCHealthcare$1.93B
0.20%
38SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.18%
39TDOC
TELADOC HEALTH INCHealthcare$1.70B
0.17%
40FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.17%
41INVA
INNOVIVA INCHealthcare$1.60B
0.16%
42IART
INTEGRA LIFESCIENCES HOLDINGS CORPHealthcare$1.50B
0.15%
43AHCO
ADAPTHEALTH CORPHealthcare$1.49B
0.15%
44PRGO
PERRIGO CO PLCHealthcare$1.48B
0.15%
45ARDT
ARDENT HEALTH INCHealthcare$1.46B
0.15%
46AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.14%
47PAHC
PHIBRO ANIMAL HEALTH CORPHealthcare$1.35B
0.14%
48CNMD
CONMED CORPHealthcare$1.30B
0.13%
49AZTA
AZENTA INCHealthcare$1.21B
0.12%
50QDEL
QUIDELORTHO CORPHealthcare$1.19B
0.12%
51TNDM
TANDEM DIABETES CARE INCHealthcare$1.17B
0.12%
52COLL
COLLEGIUM PHARMACEUTICAL INCHealthcare$1.17B
0.12%
53USPH
U S PHYSICAL THERAPY INCHealthcare$1.12B
0.11%
54CERT
CERTARA INCHealthcare$1.08B
0.11%
55LMRI
LUMEXA IMAGING HOLDINGS INCHealthcare$1.07B
0.11%
56PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.10%
57JANX
JANUX THERAPEUTICS INCHealthcare$992M
0.10%
58AMPH
AMPHASTAR PHARMACEUTICALS INCHealthcare$871M
0.09%
59GMRS
GMR SOLUTIONS INCHealthcare$721M
0.07%
60PHR
PHREESIA INCHealthcare$662M
0.07%
61CRMD
CORMEDIX INCHealthcare$661M
0.07%
62EVH
EVOLENT HEALTH INCHealthcare$654M
0.07%
63MYGN
MYRIAD GENETICS INCHealthcare$584M
0.06%
64FLGT
FULGENT GENETICS INCHealthcare$573M
0.06%
65EIKN
EIKON THERAPEUTICS INCHealthcare$529M
0.05%
66CTEV
CLARITEV CORPHealthcare$518M
0.05%
67ARVN
ARVINAS INCHealthcare$517M
0.05%
68DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.05%
69KIDS
ORTHOPEDIATRICS CORPHealthcare$494M
0.05%
70OFIX
ORTHOFIX MEDICAL INCHealthcare$468M
0.05%
71VREX
VAREX IMAGING CORPHealthcare$444M
0.05%
72CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.04%
73EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.04%
74TBRG
TRUBRIDGE INCHealthcare$394M
0.04%
75VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
0.03%
76LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.03%
77TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.03%
78RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.02%
79RXST
RXSIGHT INCHealthcare$230M
0.02%
80KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.02%
81RNA
ATRIUM THERAPEUTICS INCHealthcare$208M
0.02%
82IMUX
IMMUNIC INCHealthcare$207M
0.02%
83AMWL
AMERICAN WELL CORPHealthcare$199M
0.02%
84TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.02%
85INGN
INOGEN INCHealthcare$178M
0.02%
86KRRO
KORRO BIO INCHealthcare$177M
0.02%
87ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.02%
88LENZ
LENZ THERAPEUTICS INCHealthcare$162M
0.02%
89OPRX
OPTIMIZERX CORPHealthcare$126M
0.01%
90PTHS
PELTHOS THERAPEUTICS INCHealthcare$94M
0.01%
91PARK
PARK DENTAL PARTNERS INCHealthcare$88M
0.01%
92FRMM
FORUM MARKETS INCHealthcare$83M
0.01%
93PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.01%
94ACET
ADICET BIO INCHealthcare$76M
0.01%
95SCLX
SCILEX HOLDING COHealthcare$72M
0.01%
96LONA
LEONABIO INCHealthcare$68M
0.01%
97IMA
IMAGENEBIO INCHealthcare$61M
0.01%
98XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.01%
99MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.01%
100TIL
INSTIL BIO INCHealthcare$50M
0.01%

Full long-leg book as of July 2026 · cap-weighted · total market cap $984.79B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

100 classified
Value
Blend
Growth
Large
Mid
Small
35%9
34%10
19%4
2%9
1%5
<1%2
1%29
<1%3
<1%3

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 40% toward Growth. +8% unclassified (26 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt97% → Large
SmallLarge
Value ↔ growth tilt40% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 100 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    74.3%
    Margin
    -0.7%

    Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 100 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.3 (95% CI 0.9-1.5)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
12.4%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.29x
within
parametric
1.15x
within
cornish fisher
1.15x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2009
Before publication (pre-2009)
0.67
Sharpe · 14.1% p.a.
January 1999December 2009 · 132 mo
Since publication
-0.03
Sharpe · -0.4% p.a.
January 2010July 2026 · 199 mo
Change in Sharpe−0.70the return reversed sign — the published edge now runs the other way

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
58%
15 of 26 3-year windows made money
Worst window
-0.96
Sharpe, January 2016 – December 2018
January 1999July 2026
Median Sharpe
0.09
Dispersion
0.72
Best window
1.93

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.46.8%23.9%
3 yearsp.a.9.7%-2.3%
5 yearsp.a.5.8%-0.0%
10 yearsp.a.7.5%-3.1%
Since inceptionp.a.11.4%4.0%
Calendar years
YearLong legLong-short
20267 mo18.3%18.5%
202519.2%0.8%
2024-4.3%-15.5%
2023-4.7%-17.1%
2022-1.1%18.3%
202118.7%-1.6%
202013.9%-6.0%
201924.0%3.1%
2018-3.0%-13.0%
201711.4%-11.7%
2016-18.6%-9.0%
201518.7%8.7%
201436.2%11.2%
201349.3%-3.4%
201215.8%-5.9%
201117.4%5.8%
201011.6%3.5%
200940.8%21.4%
2008-42.3%-26.6%
200711.2%12.5%
20067.0%6.6%
200530.2%24.1%
200425.7%32.3%
200348.3%32.6%
2002-22.6%-4.7%
20019.4%33.1%
200073.3%42.5%
1999-16.4%-12.5%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FCAH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2019-04-27 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$984.79B

Methodology

The Foundry Healthcare CashProd Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a CashProd signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.